Supplemental Guarantor Financial Information Condensed Consolidating Statement of Cash Flows (Detail) (USD $) | 9 Months Ended |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings (loss) | $24,093 | $44,279 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | ' | ' |
Depreciation and amortization | 67,584 | 58,477 |
Deferred tax expense (benefit) | -9,678 | 13,257 |
Equity-based compensation expense | 7,758 | 7,681 |
Employee benefit plans | 7,801 | 6,697 |
Amortization of Financing Costs and Discounts | 4,490 | 1,508 |
Gain (Loss) on Disposition of Assets | 35 | 1,501 |
Changes in working capital, net | 47 | 51,434 |
Change in taxes receivable, net | 12,448 | -1,918 |
Excess tax benefits from equity-based payment arrangements | 0 | -9,193 |
Change in non-current accrued taxes | -10,535 | 4,161 |
Funding of qualified pension plans | -12,611 | -17,625 |
Other Operating Activities, Cash Flow Statement | 108 | 324 |
Net cash provided by operating activities | 91,540 | 160,583 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Change in short-term investments, net | -69,000 | 18,001 |
Additions to plant and equipment | -54,400 | -155,365 |
Proceeds from Sale of Productive Assets | 0 | 1,035 |
Net cash used for investing activities | -123,400 | -136,329 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Repayment of Cellu Tissue debt | -150,000 | 0 |
Payments for Repurchase of Common Stock | -75,783 | -9,355 |
Investment (to) from Parent | 0 | 0 |
Excess tax benefits from equity-based payment arrangements | 0 | 9,193 |
Payment of tax withholdings on equity-based payment arrangements | -4,173 | -12,965 |
Net cash (used for) provided by financing activities | 40,210 | -13,129 |
Increase in cash | 8,350 | 11,125 |
Cash at beginning of period | 12,579 | 8,439 |
Cash at end of period | 20,929 | 19,564 |
Proceeds from Issuance of Long-term Debt | 275,000 | 0 |
Payments of Debt Issuance Costs | -4,834 | -2 |
Issuer | ' | ' |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings (loss) | 17,839 | 44,063 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | ' | ' |
Depreciation and amortization | 40,337 | 35,244 |
Deferred tax expense (benefit) | -776 | -6,040 |
Equity-based compensation expense | 7,758 | 7,681 |
Employee benefit plans | 7,801 | 6,697 |
Amortization of Financing Costs and Discounts | 4,490 | 1,508 |
Gain (Loss) on Disposition of Assets | 0 | 487 |
Changes in working capital, net | -7,488 | 16,641 |
Change in taxes receivable, net | 11,643 | -3,121 |
Excess tax benefits from equity-based payment arrangements | ' | -9,193 |
Change in non-current accrued taxes | -10,558 | 4,631 |
Funding of qualified pension plans | -12,611 | -17,625 |
Other Operating Activities, Cash Flow Statement | 209 | 531 |
Net cash provided by operating activities | 58,644 | 81,504 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Change in short-term investments, net | -69,000 | 18,001 |
Additions to plant and equipment | -40,598 | -146,256 |
Proceeds from Sale of Productive Assets | ' | 0 |
Net cash used for investing activities | -109,598 | -128,255 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Repayment of Cellu Tissue debt | -150,000 | ' |
Payments for Repurchase of Common Stock | -75,783 | -9,355 |
Investment (to) from Parent | 19,039 | 70,454 |
Excess tax benefits from equity-based payment arrangements | ' | 9,193 |
Payment of tax withholdings on equity-based payment arrangements | -4,173 | -12,965 |
Net cash (used for) provided by financing activities | 59,249 | 57,325 |
Increase in cash | 8,295 | 10,574 |
Cash at beginning of period | 11,105 | 2,146 |
Cash at end of period | 19,400 | 12,720 |
Proceeds from Issuance of Long-term Debt | 275,000 | ' |
Payments of Debt Issuance Costs | -4,834 | -2 |
Guarantor Subsidiaries | ' | ' |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings (loss) | -9,028 | 9,580 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | ' | ' |
Depreciation and amortization | 25,590 | 21,654 |
Deferred tax expense (benefit) | -11,231 | -3,913 |
Equity-based compensation expense | 0 | 0 |
Employee benefit plans | 0 | 0 |
Amortization of Financing Costs and Discounts | 0 | 0 |
Gain (Loss) on Disposition of Assets | 34 | 1,014 |
Changes in working capital, net | 5,748 | 35,456 |
Change in taxes receivable, net | 9,153 | 1,701 |
Excess tax benefits from equity-based payment arrangements | ' | 0 |
Change in non-current accrued taxes | 19 | 59 |
Funding of qualified pension plans | 0 | 0 |
Other Operating Activities, Cash Flow Statement | -101 | -207 |
Net cash provided by operating activities | 20,184 | 65,344 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Change in short-term investments, net | 0 | 0 |
Additions to plant and equipment | -11,854 | -8,721 |
Proceeds from Sale of Productive Assets | ' | 1,035 |
Net cash used for investing activities | -11,854 | -7,686 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Repayment of Cellu Tissue debt | 0 | ' |
Payments for Repurchase of Common Stock | 0 | 0 |
Investment (to) from Parent | -8,334 | -53,194 |
Excess tax benefits from equity-based payment arrangements | ' | 0 |
Payment of tax withholdings on equity-based payment arrangements | 0 | 0 |
Net cash (used for) provided by financing activities | -8,334 | -53,194 |
Increase in cash | -4 | 4,464 |
Cash at beginning of period | 5 | 901 |
Cash at end of period | 1 | 5,365 |
Proceeds from Issuance of Long-term Debt | 0 | ' |
Payments of Debt Issuance Costs | 0 | 0 |
Non-Guarantor Subsidiaries | ' | ' |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings (loss) | -89 | 565 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | ' | ' |
Depreciation and amortization | 1,657 | 1,579 |
Deferred tax expense (benefit) | -472 | 248 |
Equity-based compensation expense | 0 | 0 |
Employee benefit plans | 0 | 0 |
Amortization of Financing Costs and Discounts | 0 | 0 |
Gain (Loss) on Disposition of Assets | 1 | 0 |
Changes in working capital, net | 1,787 | -663 |
Change in taxes receivable, net | -83 | -65 |
Excess tax benefits from equity-based payment arrangements | ' | 0 |
Change in non-current accrued taxes | 4 | -529 |
Funding of qualified pension plans | 0 | 0 |
Other Operating Activities, Cash Flow Statement | 0 | 0 |
Net cash provided by operating activities | 2,805 | 1,135 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Change in short-term investments, net | 0 | 0 |
Additions to plant and equipment | -1,948 | -388 |
Proceeds from Sale of Productive Assets | ' | 0 |
Net cash used for investing activities | -1,948 | -388 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Repayment of Cellu Tissue debt | 0 | ' |
Payments for Repurchase of Common Stock | 0 | 0 |
Investment (to) from Parent | -798 | -4,660 |
Excess tax benefits from equity-based payment arrangements | ' | 0 |
Payment of tax withholdings on equity-based payment arrangements | 0 | 0 |
Net cash (used for) provided by financing activities | -798 | -4,660 |
Increase in cash | 59 | -3,913 |
Cash at beginning of period | 1,469 | 5,392 |
Cash at end of period | 1,528 | 1,479 |
Proceeds from Issuance of Long-term Debt | 0 | ' |
Payments of Debt Issuance Costs | 0 | 0 |
Eliminations | ' | ' |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' |
Net earnings (loss) | 15,371 | -9,929 |
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: | ' | ' |
Depreciation and amortization | 0 | 0 |
Deferred tax expense (benefit) | 2,801 | 22,962 |
Equity-based compensation expense | 0 | 0 |
Employee benefit plans | 0 | 0 |
Amortization of Financing Costs and Discounts | 0 | 0 |
Gain (Loss) on Disposition of Assets | 0 | 0 |
Changes in working capital, net | 0 | 0 |
Change in taxes receivable, net | -8,265 | -433 |
Excess tax benefits from equity-based payment arrangements | ' | 0 |
Change in non-current accrued taxes | 0 | 0 |
Funding of qualified pension plans | 0 | 0 |
Other Operating Activities, Cash Flow Statement | 0 | 0 |
Net cash provided by operating activities | 9,907 | 12,600 |
CASH FLOWS FROM INVESTING ACTIVITIES | ' | ' |
Change in short-term investments, net | 0 | 0 |
Additions to plant and equipment | 0 | 0 |
Proceeds from Sale of Productive Assets | ' | 0 |
Net cash used for investing activities | 0 | 0 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' |
Repayment of Cellu Tissue debt | 0 | ' |
Payments for Repurchase of Common Stock | 0 | 0 |
Investment (to) from Parent | -9,907 | -12,600 |
Excess tax benefits from equity-based payment arrangements | ' | 0 |
Payment of tax withholdings on equity-based payment arrangements | 0 | 0 |
Net cash (used for) provided by financing activities | -9,907 | -12,600 |
Increase in cash | 0 | 0 |
Cash at beginning of period | 0 | 0 |
Cash at end of period | 0 | 0 |
Proceeds from Issuance of Long-term Debt | 0 | ' |
Payments of Debt Issuance Costs | $0 | $0 |